Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
- 1 May 2010
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (5) , 465-475
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- Aflibercept in Epithelial Ovarian CarcinomaFuture Oncology, 2009
- Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor TherapyClinical Cancer Research, 2009
- Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinibBritish Journal of Cancer, 2008
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortiaGynecologic Oncology, 2008
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey ResultsOncology, 2007
- Structural reengineering of imatinib to decrease cardiac risk in cancer therapyJournal of Clinical Investigation, 2007
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Cardiovascular Complications of Cancer TherapyCirculation, 2004